The research publication of the in vivo genome editing project for congenital muscular dystrophy in T-CiRA Joint Program (Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice)
were published online in Nature Communications on December 8th 2021.
1 T-CiRA Discovery, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
2 Takeda-CiRA Joint Program (T-CiRA), Kanagawa, Japan
3 Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan